Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 1Phase 3 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4Myeloid 1

Conditions

Lymphoma 4Leukemia 4Hyperuricemia 4Leukemia, Myeloid, Acute 3Tumor Lysis Syndrome 2Burkitt Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nutritional and Metabolic Diseases 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Cyclophosphamide 178Cytarabine 110fludarabine phosphate 102Methotrexate 98Busulfan 90Filgrastim 80Rituximab 72Peripheral Blood Stem Cell Transplantation 69Cyclosporine 60Radiotherapy 57Etoposide 57Mycophenolic Acid 56Antilymphocyte Serum 56fludarabine 55Tacrolimus 55Vincristine 47Whole-Body Irradiation 44Melphalan 42Dexamethasone 39Granulocyte Colony-Stimulating Factor 38sargramostim 34Methylprednisolone 34Alemtuzumab 34Daunorubicin 33Imatinib Mesylate 32Mercaptopurine 28Prednisone 26Idarubicin 26Doxorubicin 25Leucovorin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Leukemia × rasburicase × Clear all
NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

M.D. Anderson Cancer Center

Phase 2 Completed
55 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 2 Completed
82 enrolled 6 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

NCT00631579 2009-10-02

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

Sanofi

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Hyperuricemia

NCT00290992 2009-03-30

Rasburicase for Hyperuricemia

Sanofi

Phase 2 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Nutritional and Metabolic Diseases, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡